Principal Financial Group Inc. boosted its stake in shares of Chemed Corporation (NYSE:CHE – Free Report) by 3.7% during the first quarter, HoldingsChannel.com reports. The firm owned 31,598 shares of the company’s stock after acquiring an additional 1,135 shares during the period. Principal Financial Group Inc.’s holdings in Chemed were worth $11,936,000 as of its most recent SEC filing.
Several other large investors have also recently added to or reduced their stakes in CHE. Northwestern Mutual Wealth Management Co. lifted its position in Chemed by 2,444,879.3% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 5,550,103 shares of the company’s stock worth $2,374,667,000 after buying an additional 5,549,876 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Chemed by 4.4% during the 4th quarter. JPMorgan Chase & Co. now owns 521,900 shares of the company’s stock valued at $223,301,000 after acquiring an additional 21,932 shares in the last quarter. AQR Capital Management LLC grew its holdings in shares of Chemed by 89.2% during the 4th quarter. AQR Capital Management LLC now owns 325,579 shares of the company’s stock valued at $139,302,000 after acquiring an additional 153,469 shares in the last quarter. TD Asset Management Inc increased its stake in shares of Chemed by 7.5% in the fourth quarter. TD Asset Management Inc now owns 324,546 shares of the company’s stock worth $138,860,000 after acquiring an additional 22,715 shares during the last quarter. Finally, Epoch Investment Partners Inc. increased its stake in shares of Chemed by 4.9% in the fourth quarter. Epoch Investment Partners Inc. now owns 322,408 shares of the company’s stock worth $137,945,000 after acquiring an additional 15,133 shares during the last quarter. Institutional investors and hedge funds own 95.85% of the company’s stock.
Wall Street Analysts Forecast Growth
CHE has been the subject of a number of research reports. Weiss Ratings raised Chemed from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, July 17th. Zacks Research raised Chemed from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Wall Street Zen downgraded Chemed from a “buy” rating to a “hold” rating in a research note on Monday, June 8th. Bank of America lifted their price target on Chemed from $450.00 to $510.00 and gave the company a “neutral” rating in a report on Thursday, July 9th. Finally, Royal Bank Of Canada boosted their price target on Chemed from $422.00 to $436.00 and gave the company a “sector perform” rating in a research note on Monday, April 27th. One analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Chemed has an average rating of “Hold” and an average target price of $480.25.
Insider Buying and Selling
In other news, Director Andrea R. Lindell sold 1,347 shares of the company’s stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $447.33, for a total transaction of $602,553.51. Following the completion of the transaction, the director directly owned 4,578 shares in the company, valued at $2,047,876.74. The trade was a 22.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Kevin J. Mcnamara sold 2,000 shares of the stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $421.13, for a total value of $842,260.00. Following the completion of the sale, the chief executive officer directly owned 90,219 shares of the company’s stock, valued at $37,993,927.47. This represents a 2.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 3.33% of the company’s stock.
Chemed Stock Up 1.4%
CHE stock opened at $510.28 on Friday. The stock has a market capitalization of $6.77 billion, a price-to-earnings ratio of 27.81, a price-to-earnings-growth ratio of 1.85 and a beta of 0.52. The company has a 50-day moving average of $458.59 and a two-hundred day moving average of $433.65. Chemed Corporation has a 52-week low of $365.20 and a 52-week high of $517.74. The company has a debt-to-equity ratio of 0.11, a current ratio of 0.85 and a quick ratio of 0.83.
Chemed (NYSE:CHE – Get Free Report) last posted its quarterly earnings data on Thursday, April 23rd. The company reported $5.65 EPS for the quarter, topping analysts’ consensus estimates of $5.30 by $0.35. Chemed had a return on equity of 27.18% and a net margin of 10.23%.The business had revenue of $657.51 million for the quarter, compared to analyst estimates of $659.22 million. During the same period in the previous year, the company posted $5.63 earnings per share. The firm’s revenue for the quarter was up 1.6% on a year-over-year basis. As a group, equities research analysts anticipate that Chemed Corporation will post 22.67 EPS for the current year.
Chemed Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 16th. Shareholders of record on Thursday, May 28th were issued a $0.60 dividend. The ex-dividend date of this dividend was Thursday, May 28th. This represents a $2.40 dividend on an annualized basis and a yield of 0.5%. Chemed’s dividend payout ratio (DPR) is 13.08%.
Chemed Company Profile
Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.
The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.
Featured Articles
- Five stocks we like better than Chemed
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
- CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
- Plugging In: How Kinder Morgan Powers Up Profits
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corporation (NYSE:CHE – Free Report).
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.
